Royalty Pharma plc (Nasdaq: RPRX) today announced a research and development (R&D) co-funding agreement with Johnson & Johnson for a total of $500 million in 2026 and 2027 to advance the development ...
TrumpRx/MFN pricing risks could pressure margins despite 9.3x fwd P/E, 6.27% dividend and pipeline gains. Read the latest ...
Pfizer Inc. (NYSE:PFE) is one of the best undervalued stocks under $50 to invest in now. Pfizer Inc. (NYSE:PFE) announced on ...
2d
Should Pfizer’s (PFE) New Lyme Vaccine and Oncology Wins Reshape Its Post‑COVID Pipeline Story?
In March 2026, Pfizer and partner Valneva reported that their investigational 6‑valent OspA-based Lyme disease vaccine achieved roughly three‑quarters efficacy in a Phase 3 trial, while separate ...
Pfizer reported positive phase 2 results for atirmociclib in metastatic breast cancer, adding a new oncology asset to its ...
Investing.com -- Damora Therapeutics Inc (NASDAQ:DMRA) shares jumped 15.5% Monday following the announcement of Jennifer ...
MedPage Today on MSN
Estradiol Patch Matches LHRH Agonists for Locally Advanced Prostate Cancer
Similar 3-year metastasis-free survival, fewer hot flashes, more gynecomastia ...
Royalty Pharma plc (Nasdaq: RPRX) today announced the appointment of Lucas Glass as Head of Artificial Intelligence, effective April 2026. Lucas will lead ...
Ms. Jarrett brings nearly three decades of executive leadership in biotech, tech and finance -- -- Biotech leaders Dr. Cameron Turtle and Mike Landsittel appointed to Board of Directors -- -- Peter ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results